Yes - sub 40 cents after a second CRL was seen by most insto’s...

Yes - sub 40 cents after a second CRL was seen by most insto’s that MSB was at failure point.

Not much at all was priced in for success.

Now table has turned with FDA management it seems and a supportive stance across various announcements in the last 6 months.

MSB back on track to execute original plan as well a potentially progressing HF therapies in faster approval manner.

The near term value now due to both Adult aGVHD and HF LVAD therapies looking like there is a faster approval path is quite substantial. That is an decent understatement.

$1 share price and 1 Billion market cap is not even close to valuing MSB correctly for what is now being proposed by MSB on current approval plans.

There is still a heck of a lot of risk baked into the share price still but should it be???? GG and the BOD who know what the direct communication with the MSB and FDA looks like, they are buying a lot of shares, many doubling down. These investors as a collective are not dumb people.

The SP is about to change….first approval validates Ryoncil, validates MSB Managements plan and methodology, validates the entire MSC platform of therapies, validates any doubt of how needed the compassionate use of Rem-L and MSC’s has been needed in hospitals for the last decade or so.

Waiting patiently for the correct valuation of MSB and the demand to fully kick in accordingly.